Endocrine Abstracts

Introduction: • The incidence of primary hyperparathyroidism (PHPT) in Scotland is approximately 3.5/100 000 per year.

• The incidence is probably on the rise due to increase in ‘routine biochemical testing’

• Some patients tend to undergo surgery, while others are conservatively treated and most followed up for a short period before discharge from follow up.

Aims: • Determine if risk of cancer is increased in patients with primary hyperparathyroidism (PHPT).

• Determine if mortality is increased in patients with primary hyperparathyroidism.

Methodology: • A cohort of patients with PHPT between1981–2007, was identified from the Scottish Morbidity records and linked to the Scottish Cancer Registry and Scottish Mortality records.

• Patients with pre-existing cancers (or developing cancer within one year of diagnosis of PHPT) were excluded from the analysis of subsequent cancer risks.

• The prevalence of new cancers and deaths was identified in these patients.

• The results were then compared with the risk of cancer and mortality in the general population living in Scotland.

Outcome/results: • Total number of patients diagnosed with PHPT: 3039.

• Females: 2350 (77.3%), Males: 689 (22.7%).

• Mean age of patients: 63.5 years.

• Person years at risk of cancer: 22 710.

• New cases of cancer: 440/2706.

• Standardised incidence rate of cancer: (SIR): 2.026, 95% CI (1.841–2.224), P<0.001.

• Person years at risk of death: 24 186.

• Number of deaths: 1601.

• Standardised incidence rate of deaths: (SIR): 3.085, 95% CI (2.936–3.240) P<0.001.

Conclusions: • Individuals with PHPT have a 2 fold increased risk of developing subsequent cancer and a 3 fold increased risk of death as compared to general population.

• The findings of this study have enormous implications for management and follow up of patients diagnosed with primary hyperparathyroidism.